Table 1. Association of APOBEC3B mRNA expression with clinicopathological characteristics of the primary tumor.
| APOBEC3B mRNA log2 | AVG epithelial mRNA log2 | PTPRC (CD45) mRNA log2 | ||||||
|---|---|---|---|---|---|---|---|---|
| Clinical characteristics | No of patients* | Percentage of patients | Median | IQR | Median | IQR | Median | IQR≠ |
| All patients in this cohort | 55 | 100% | -6.14 | -5.28 | -3.11 | -1.25 | -2.98 | -2.31 |
| Age at surgery (years) | ||||||||
| ≤ 40 | 10 | 18% | -6.69 | -4.62 | -2.74 | -1.40 | -2.31 | -2.89 |
| 41–55 | 21 | 38% | -5.80 | -5.95 | -3.23 | -1.46 | -3.14 | -1.41 |
| 56–70 | 20 | 36% | -6.64 | -4.16 | -3.03 | -1.25 | -3.48 | -7.68 |
| > 70 | 5 | 9% | -6.04 | -2.08 | -2.93 | -0.54 | -2.40 | -1.09 |
| P≠ | 0.76 | 0.52 | 1.00 | |||||
| Tumor size | ||||||||
| ≤ 2 cm | 17 | 31% | -6.14 | -6.31 | -3.03 | -0.94 | -2.72 | -2.28 |
| 2 ≤ 5 cm | 27 | 49% | -5.92 | -2.25 | -2.93 | -1.40 | -3.62 | -7.65 |
| > 5 cm | 7 | 13% | -6.91 | -4.07 | -3.17 | -1.19 | -3.27 | -1.69 |
| P≠ | 0.70 | 0.95 | 0.88 | |||||
| Histopathological subtypes† | ||||||||
| Ductal | 43 | 78% | -5.80 | -4.65 | -2.93 | -1.41 | -3.27 | -1.76 |
| Lobular | 8 | 15% | -8.50 | -3.92 | -3.14 | -0.85 | -2.31 | -4.90 |
| Other | 4 | 7% | -6.43 | -3.19 | -3.37 | -0.58 | -1.23 | -2.24 |
| P$ | 0.07 | 0.41 | 0.31 | |||||
| Bloom & Richardson grade | ||||||||
| I + II | 10 | 18% | -6.39 | -4.78 | -3.11 | -1.51 | -6.94 | -7.56 |
| III | 38 | 69% | -5.78 | -4.65 | -3.15 | -1.33 | -2.92 | -2.37 |
| P$ | 0.43 | 0.52 | 0.08 | |||||
| ESR1 status | ||||||||
| Negative | 22 | 40% | -5.64 | -3.79 | -2.91 | -1.24 | -3.06 | -2.00 |
| Positive | 33 | 60% | -6.40 | -4.69 | -3.17 | -1.35 | -2.98 | -2.81 |
| P$ | 0.15 | 0.39 | 0.88 | |||||
| ERBB2 status | ||||||||
| Negative | 43 | 78% | -5.80 | -5.01 | -3.19 | -1.06 | -2.97 | -2.90 |
| Positive/amplified | 12 | 22% | -7.35 | -3.70 | -2.77 | -1.59 | -3.31 | -1.67 |
| P$ | 0.04 | 0.11 | 0.96 | |||||
| Regional lymph node status | ||||||||
| Negative | 16 | 29% | -5.64 | -4.40 | -3.17 | -1.14 | -2.84 | -2.63 |
| Positive | 33 | 60% | -6.40 | -4.62 | -3.00 | -1.17 | -2.98 | -1.84 |
| P$ | 0.23 | 0.74 | 0.90 | |||||
| Time between primary tumor and studied metastasis | ||||||||
| ≤ 24 months | 33 | 60% | -5.92 | -5.45 | -2.88 | -1.16 | -2.85 | -2.09 |
| > 24 months | 22 | 40% | -6.43 | -4.09 | -3.24 | -0.93 | -3.20 | -2.28 |
| P≠ | 0.97 | 0.42 | 0.33 | |||||
| Overall survival status | ||||||||
| Alive | 22 | 40% | -5.92 | -2.52 | -3.11 | -1.48 | -3.67 | -8.34 |
| Deceased | 33 | 60% | -6.65 | -5.03 | -3.11 | -0.95 | -2.81 | -1.68 |
| P$ | 0.21 | 0.62 | 0.20 | |||||
AVG epithelial; average mRNA level of KRT19 and EPCAM. IQR; interquartile range.
* Due to missing values numbers do not always add up to 55.
≠ Spearman correlation significance (2-tailed).
$ Mann-Whitney Test significance (2-tailed).
† mRNA expression of ductal and lobular breast cancer was compared.